-$0.50 Earnings Per Share Expected for Heron Therapeutics, Inc. (NASDAQ:HRTX) This Quarter

Equities research analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) will post ($0.50) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.36). Heron Therapeutics reported earnings of ($0.62) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($1.97) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.57). For the next financial year, analysts anticipate that the business will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.51) to ($1.01). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.18). Heron Therapeutics had a negative net margin of 258.35% and a negative return on equity of 243.85%. The business had revenue of $23.46 million during the quarter, compared to the consensus estimate of $22.61 million. During the same period in the prior year, the firm earned ($0.58) EPS. The business’s revenue for the quarter was up 17.2% on a year-over-year basis.

HRTX has been the subject of a number of recent analyst reports. Cantor Fitzgerald cut their price target on shares of Heron Therapeutics from $20.00 to $12.00 in a report on Tuesday, May 10th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 9th. Cowen cut their price target on shares of Heron Therapeutics from $13.00 to $7.50 in a report on Tuesday, May 10th. Needham & Company LLC lowered their price objective on shares of Heron Therapeutics from $24.00 to $16.00 in a research report on Tuesday, March 1st. Finally, StockNews.com started coverage on shares of Heron Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating for the company.

Shares of Heron Therapeutics stock traded up $0.11 on Friday, reaching $3.29. 75,931 shares of the stock were exchanged, compared to its average volume of 2,320,433. The firm’s 50 day moving average is $4.87 and its 200-day moving average is $7.26. Heron Therapeutics has a one year low of $3.05 and a one year high of $16.63. The company has a debt-to-equity ratio of 6.22, a quick ratio of 1.79 and a current ratio of 2.39. The firm has a market cap of $337.16 million, a PE ratio of -1.43 and a beta of 1.37.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Heron Therapeutics by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,612,375 shares of the biotechnology company’s stock worth $17,236,000 after buying an additional 22,983 shares during the last quarter. Balyasny Asset Management LLC increased its position in Heron Therapeutics by 22.8% during the 3rd quarter. Balyasny Asset Management LLC now owns 480,772 shares of the biotechnology company’s stock valued at $5,139,000 after purchasing an additional 89,339 shares during the period. Crestline Management LP purchased a new position in Heron Therapeutics during the 3rd quarter valued at $1,099,000. Cubist Systematic Strategies LLC grew its position in shares of Heron Therapeutics by 135.5% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 87,145 shares of the biotechnology company’s stock worth $932,000 after buying an additional 50,141 shares during the period. Finally, ArrowMark Colorado Holdings LLC boosted its stake in Heron Therapeutics by 8.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 6,421,335 shares of the biotechnology company’s stock worth $68,644,000 after purchasing an additional 517,367 shares in the last quarter.

About Heron Therapeutics (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Stories